DR. GREGORY A DEMOPULOS, MD
Medical Practice at Forest Ave, Mercer Island, WA

6413961, Jul 2, 2002

Sep 1, 1999

09/388837

Gregory A. Demopulos - Mercer Island WA
Pamela Anne Pierce - San Francisco CA
Jeffrey M. Herz - Mill Creek WA

Omeros Medical Systems, Inc. - Seattle WA

A61K 31535

5142392, 514304, 514311, 514330, 514535, 514537, 514619, 514626

A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general surgical, therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents, including at least one local anesthetic agent, and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringers solution. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also include anti-restenosis agents.

6645168, Nov 11, 2003

Jul 12, 2002

10/195625

Gregory A. Demopulos - Mercer Island WA
Pamela A. Pierce - Tiburon CA
Jeffrey M. Herz - Mill Creek WA

Omeros Corporation - Seattle WA

A61M 3100

604 49, 604500, 514654

A method and solution for perioperatively inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes multiple pain and inflammation inhibitory at dilute concentration in a physiologic carrier, such as saline or lactated Ringers solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain and inflammation includes a serotonin antagonist, a serotonin antagonist, a histamine antagonist, a serotonin agonist, a cyclooxygenase inhibitor, a neurokinin antagonist, a neurokinin antagonist, a purinoceptor antagonist, an ATP-sensitive potassium channel opener, a calcium channel antagonist, a bradykinin antagonist, a bradykinin antagonist and a -opioid agonist.

6056715, May 2, 2000

May 4, 1998

9/072755

Gregory A. Demopulos - Mercer Island WA
Pamela A. Pierce - Tiburon CA
Jeffrey M. Herz - Mill Creek WA

Omeros Medical Systems, Inc. - Seattle WA

A61M 3100

604 49

A method and solution for perioperatively inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes multiple pain and inflammation inhibitory at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain and inflammation includes a serotonin. sub. 2 antagonist, a serotonin. sub. 3 antagonist, a histamine antagonist, a serotonin agonist, a cyclooxygenase inhibitor, a neurokinin. sub.

2011009, Apr 21, 2011

Oct 15, 2010

12/905972

Hans-Wilhelm Schwaeble - Mountsorrel, GB
Thomas Dudler - Bellevue WA, US
Clark E. Tedford - Poulsbo WA, US
James B. Parent - Bainbridge Island WA, US
Gregory A. Demopulos - Mercer Island WA, US

OMEROS CORPORATION - Seattle WA
UNIVERSITY OF LEICESTER - Leicestershire

A61K 39/395, A61K 38/48, A61K 38/17, A61P 35/00, A61P 37/06, A61P 7/00, A61P 31/04, A61P 9/00, A61P 1/16, A61P 43/00, A61P 25/00

4241321, 4241391, 4241331, 424 9464, 514 137, 514 24, 514 14

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

2008026, Oct 23, 2008

Mar 27, 2008

12/057368

John E. Bergmann - Mercer Island WA, US
Neil S. Cutshall - Snohomish WA, US
Gregory A. Demopulos - Mercer Island WA, US
Vincent A. Florio - Seattle WA, US
George Gaitanaris - Seattle WA, US
Patrick Gray - Seattle WA, US
John Hohmann - LaConner WA, US
Rene Onrust - Mercer Island WA, US
Hongkui Zeng - Shoreline WA, US

OMEROS CORPORATION - Seattle WA

A61K 31/433, A61K 31/195, A61K 31/519, A61P 25/00, A61P 25/28, A61K 51/04, A61K 31/527

424 92, 514567, 5142621, 514257, 514363

A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

8006700, Aug 30, 2011

Apr 2, 2002

10/114709

Gregory A. Demopulos - Mercer Island WA, US
Scott W. Reed - Monroe CT, US
Alan B. Bachman - Milford CT, US
Frederick T. Karl - Newtown CT, US
William J. Allen - Stratford CT, US
Leland Ray Adams - Ansonia CT, US
G. Lawrence Thatcher - Chelmsford MA, US

A61B 19/00

128898, 606213, 606300

A medical fastener (), preferably bioabsorbable, is used for repairing torn soft tissue, particularly meniscal tissue (). The fastener () can have an enlarged head () at the proximate end to engage meniscal tissue () adjacent to a tear (), and a pointed distal tip () at the other end to ease insertion of the fastener () into the meniscus (). The shank () of the fastener () bridges across the tear (). Opposite ends of the shank () are secured in the meniscal tissue () by a medical adhesive, preferably bioabsorbable, and preferably at locations remote from the tear () so as not to interfere with healing of the tear (). The fastener () can have a blind bore () opening through the head () of the fastener () and extending through the shank () to a location close to the tip () and generally radial holes () communicating between the bore () and the exterior of the shank (). The medical adhesive can be injected through the bore () for passage outward through the holes ().

2003003, Feb 13, 2003

Jul 2, 2002

10/189335

Gregory Demopulos - Mercer Island WA, US
Pamela Palmer - San Francisco CA, US

Omeros Corporation

A61K031/4747

514/278000

A method of producing analgesia in a mammal is provided by intrathecal administration to the mammal of a pharmaceutically effective dose of the opioid receptor-like receptor 1 (ORL-1) agonist (1S,3aS)8-(2,3,3a,4,5,6-hexahydro-IH-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4,5]decan-4-one. Administration may be carried out through use of an implantable apparatus.

5800544, Sep 1, 1998

Dec 4, 1995

8/567311

Gregory A. Demopulos - Mercer Island WA
Stephen A. Yencho - Stanford CA
David A. Herrin - Seattle WA
Neil G. McIlvaine - Seattle WA
Michael D. Nelson - Seattle WA
Milton R. Sigelmann - Seattle WA
Jose T. V. de Castro - Newtown MA
George Selecman - Marblehead MA
John Collins - Ipswich MA
Imraan Aziz - Stanford CA
Gorm Bressner - Providence RI

Omeros Medical Systems, Inc. - Seattle WA

A61F 208

623 13

The damaged portion of an injured tendon or ligament (C) ("connective cord") is inserted into a thin, hollow sleeve (100, 110, 120, 130, 140, 160, 180, 200, 240, 260, 270, 300, 390, generically designated "S") and is connected to the sleeve (S) such that the cord-sleeve combination can immediately withstand normal tensile forces. the interconnection can be mechanical, such as by pins (22, 22', 148, 150, 164, 188, 190, 206, 206', 210, 226, 230, 238, 239, 266, 286, 308) extending through the sleeve (S) and cord (C). The sleeve (S) can be bioabsorbable over a sufficiently long period of time that the cord (C) is healed by the time the sleeve (S) is absorbed.

2010002, Feb 4, 2010

Jan 21, 2009

12/321488

Gregory A. Demopulos - Mercer Island WA, US
Pamela Anne Pierce - San Francisco CA, US
Jeffrey M. Herz - Mill Creek WA, US

A61K 31/4418, A61K 31/245, A61K 31/164, A61K 31/445, A61P 25/00

514305, 514535, 514626, 514331

A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general surgical, therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents, including at least one local anesthetic agent, and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also include anti-restenosis agents.

2012023, Sep 20, 2012

Apr 24, 2012

13/454926

Gregory A. Demopulos - Mercer Island WA, US
Jeffrey M. Herz - Mill Creek WA, US

OMEROS CORPORATION - Seattle WA

A61M 37/00, A61K 31/435, A61P 29/00, A61K 9/00, A61P 13/00, A61P 25/00, A61K 31/19, A61K 31/4422

604 20, 514570, 514277, 514356, 424422, 604 22

Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.